Aeglea BioTherapeutics Inc

NASDAQ:AGLE  
8.22
-0.20 (-2.38%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)391.80M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$4.01 Million
Adjusted EPS-$0.28
See more estimates
10-Day MA$8.05
50-Day MA$7.34
200-Day MA$7.35
See more pivots

Aeglea BioTherapeutics Inc Stock, NASDAQ:AGLE

805 Las Cimas Parkway, Suite 100, Austin, Texas 78746
United States of America
Phone: +1.512.942.2935
Number of Employees: 90

Description

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.